Brief: Terns Pharmaceuticals Q2 Net Income USD -24.093 Million Vs. IBES Estimate USD -26.6 Million

Terns Pharmaceuticals

05/08/2025 21:05

Overview

Terns Q2 net income, income from operations beat analyst expectations

Company advancing TERN-701 in CML, TERN-601 in obesity trials

Cash runway into 2028, focusing on oncology, seeking metabolic partners

Outlook

Terns expects Phase 1 CARDINAL trial data in Q4 2025

Company plans no further investment in metabolic disease beyond 2025

Terns anticipates Phase 2 FALCON trial results early Q4 2025

Company has cash runway into 2028, focusing on CML program

Result Drivers

CML PROGRAM - Rapid enrollment in TERN-701 Phase 1 trial for CML with dose expansion initiated due to favorable safety and efficacy data

OBESITY TRIAL - Completed enrollment for Phase 2 trial of TERN-601 for obesity; data expected early 4Q25

FOCUS SHIFT - Company to focus on advancing TERN-701 for CML and seek partners for metabolic assets

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Income
Beat
-$24.09 mln
-$26.60 mln (5 Analysts)
Q2 Income from Operations
Beat
-$27.38 mln
-$29.10 mln (6 Analysts)
Q2 Pretax Profit
Beat
-$24.03 mln
-$26.60 mln (5 Analysts)
Q2 Basic EPS
-$0.26
Q2 Operating Expenses
$27.38 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Terns Pharmaceuticals Inc is $17.00, about 66.2% above its August 4 closing price of $5.75

Press Release: ID:nGNX3tqNx5

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)